ライフサイエンスコーパス: P-glycoprotein

1 likelihood of brain uptake being affected by P-glycoprotein.

2 t olaparib-resistant tumors that overexpress P-glycoprotein.

3 ier-related ATP-binding cassette transporter P-glycoprotein.

4 e, which encodes the drug efflux transporter P-glycoprotein.

5 osis transmembrane conductance regulator and P-glycoprotein.

6 dues for interaction of small molecules with P-glycoprotein.

7 llin was associated with an interaction with P-glycoprotein.

8 d by multiple ABC transporters, particularly P-glycoprotein.

9 rom the fetus toward the mother by placental P-glycoprotein.

10 and circumvented drug resistance mediated by P-glycoprotein.

11 and Messa/Dx5 cell lines, which overexpress P-glycoprotein.

12 did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein.

13 of multidrug resistant cells overexpressing P-glycoprotein.

14 rapies with limited brain penetration due to P-glycoprotein.

15 rst-pass metabolism, and efficient efflux by P-glycoprotein.

16 model of substrate and inhibitor coupling to P-glycoprotein.

17 kely an efficiently transported substrate of P-glycoprotein.

18 may be influenced by the multi-drug exporter P-glycoprotein.

19 ma serum stability and is not a substrate of P-glycoprotein 1 (permeability glycoprotein) advancing i

20 sm, and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive perme

21 have cleavage activities on its target gene P-glycoprotein 11, a broad substrate efflux pump across

22 as shown in vitro to be a substrate of human P-glycoprotein, a drug-transporter involved in all steps

23 P-glycoprotein (ABC subfamily B member 1, ABCB1) plays a

24 e ATP-binding cassette family like the human P-glycoprotein (ABCB1 or Pgp) are responsible for many f

25 e triphosphate-binding cassette transporters P-glycoprotein (ABCB1) and breast cancer resistance prot

26 barrier (BBB) because of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance prot

27 P-glycoprotein (ABCB1) is expressed at the blood-retina

28 P-glycoprotein (ABCB1) plays an important role at the bl

29 PET with avid substrates of P-glycoprotein (ABCB1) provided evidence of the role of

30 tte (ABC) transmembrane efflux pumps such as P-glycoprotein (ABCB1), multidrug resistance protein 1 (

31 itors that were high-affinity substrates for p-glycoprotein (ABCB1), the multidrug resistance protein

32 oprotein and its human counterpart, the MDR1 P-glycoprotein, ABCB1.

33 ls of TAP built on the crystal structures of P-glycoprotein, ABCB10, and Sav1866.

34 g cassette (ABC) transporters such as ABCB1 (P-glycoprotein), ABCC1 (MRP1), and ABCG2 (BCRP) are well

35 ABCB1, also known as P-glycoprotein, actively extrudes xenobiotic compounds a

36 t that reduced rCBF has on assessment of BBB P-glycoprotein activity and suggests that impaired P-gly

37 20P, can rapidly and reversibly reduce basal P-glycoprotein activity and thus improve delivery of sma

38 BBB P-glycoprotein activity in brain regions affected by AD

39 We compared P-glycoprotein activity in mild-AD patients (n = 9) and

40 tivity and protein expression; SFN increased P-glycoprotein activity in mouse spinal cord capillaries

41 We assessed P-glycoprotein activity in vivo in patients with tempora

42 2 are required for C1P-mediated increases in P-glycoprotein activity independent of transporter prote

43 We tested the hypothesis that BBB P-glycoprotein activity is diminished in Alzheimer disea

44 oprotein activity and suggests that impaired P-glycoprotein activity may contribute to cerebral beta-

45 Higher P-glycoprotein activity was associated with higher seizu

46 BBB P-glycoprotein activity was expressed as the (11)C-verap

47 Compared with controls, BBB P-glycoprotein activity was significantly lower in the p

48 ed ABC transporter expression, and inhibited P-glycoprotein activity, suggesting direct binding and i

49 aseline K1, corresponding to higher baseline P-glycoprotein activity, than seizure-free patients in i

50 ) blocked the effects of SFN and nutlin-3 on P-glycoprotein activity.

51 on, and the p53-activator nutlin-3 increased P-glycoprotein activity.

52 ion or translation abolished upregulation of P-glycoprotein activity.

53 ncreases after tariquidar correspond to high P-glycoprotein activity.

54 of specific genes and significantly elevated p-glycoprotein activity.

55 of multiple sclerosis, also rapidly reduced P-glycoprotein activity; similar effects were found with

56 scopy to uncover the basis of stimulation of P-glycoprotein adenosine 5'-triphosphate (ATP) hydrolysi

57 tracers to assess the transport activity of P-glycoprotein (adenosine triphosphate-binding cassette

58 Structural comparison of MRP1 and P-glycoprotein advances our understanding of the common

59 P-glycoprotein, an ATP-driven drug efflux pump, is a maj

60 P-glycoprotein, an ATP-driven efflux pump, regulates per

61 vels of the ATP-binding cassette transporter P-glycoprotein, an efflux transporter known to detoxify

62 multidrug efflux protein MDR1 (also known as P-glycoprotein and ABCB1).

63 MSCs overexpress efflux transporters such as P-glycoprotein and are highly drug resistant.

64 nNOS inhibition but also a significantly low P-glycoprotein and breast-cancer-resistant protein subst

65 (ii) this overexpression appears specific to P-glycoprotein and does not affect other transporters; (

66 be excellent substrates of the murine ABCB1A P-glycoprotein and its human counterpart, the MDR1 P-gly

67 -hydroxyeicosatetraenoic acid that regulated P-glycoprotein and junction proteins, respectively, ther

68 onfirmed their potential to inhibit the fish P-glycoprotein and modulate toxicity of other xenobiotic

69 ve, namely, 1p, was selective for ABCG2 over P-glycoprotein and MRP1, appeared not to be transported

70 class of galloyl-based modulators targeting P-glycoprotein and MRP1.

71 anisms of drug resistance, the expression of P-glycoprotein and the betaIII isotype of tubulin.

72 rug resistance mediated by the expression of P-glycoprotein and the betaIII isotype of tubulin.

73 onolayer and that PHIP-M1 is a substrate for P-glycoprotein and the multiple drug resistance 2 transp

74 porters include ABCB1 (also known as MDR1 or P-glycoprotein) and ABCC1 (also known as MRP1) whose inh

75 ining l-asparaginase and drugs unaffected by P-glycoprotein are most effective.

76 Mammalian P-glycoproteins are active drug efflux transporters loca

77 and selective downregulation of endothelial p-glycoprotein at the blood-brain barrier that occurs in

78 rug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidr

79 Measurement of the P-glycoprotein-ATPase activity as a function of concentr

80 t unexpectedly strong down-modulation of the P-glycoprotein-ATPase by certain detergents.

81 P-glycoprotein-ATPase inhibition due to membrane disorde

82 P-glycoprotein-ATPase is an efflux transporter of broad

83 2, p53, and NF-kappaB in the upregulation of P-glycoprotein, Bcrp, and Mrp2 at blood-CNS barriers.

84 or mouse brain capillaries to SFN increased P-glycoprotein, Bcrp, and Mrp2 transport activity and pr

85 If this relation is confirmed, and P-glycoprotein can be identified as a contributor to pha

86 y the ATP-binding cassette (ABC) transporter P-glycoprotein contributes to clinical resistance to ant

87 Inhibition of P-glycoprotein could partly resensitize sarcomatoid tumo

88 Our results demonstrated P-glycoprotein decreases bumped kinase inhibitor enteroc

89 lpighamoeba infection on fluid secretion and P-glycoprotein-dependent detoxification by desert locust

90 Infection also impairs P-glycoprotein-dependent detoxification by reducing the

91 Coupled with reduced efficiency of P-glycoprotein detoxification per surface area, Malpigha

92 s novel, acting to indirectly interfere with P-glycoprotein drug efflux activity as a consequence of

93 ral drug-resistant cell lines with activated P-glycoprotein drug efflux pumps compared to drug-sensit

94 cing tubulin polymerization while inhibiting P-glycoprotein drug efflux.

95 The P-glycoprotein drug pump protects us from toxins.

96 um infection, we characterized the effect of P-glycoprotein efflux on bumped kinase inhibitor pharmac

97 sed with drug concentration and exceeded the p-glycoprotein efflux when the latter was saturated.

98 properties such as permeation and especially P-glycoprotein efflux.

99 long-acting, and noncompetitive modulator of P-glycoprotein export function that may offer therapeuti

100 thase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brai

101 t to doxorubicin despite significantly lower P-glycoprotein expression in the DoxR-v cells.

102 enhanced DNA damage and obvious reduction of P-glycoprotein expression in the resistant cells treated

103 P-glycoprotein expression is known to be controlled by g

104 tance, and that the specific upregulation of P-glycoprotein expression is likely to be associated wit

105 etained in cancerous kidney tissues with low P-glycoprotein expression.

106 )C-laniquidar is a newly developed tracer of P-glycoprotein expression.

107 ood-brain barrier permeability and increased P-glycoprotein expression.

108 axel response, despite an increase in Abcb1 (P-glycoprotein) expression that was sufficient to explai

109 ineties, we generated knockouts of the three P-glycoprotein genes of mice, the Mdr1a, Mdr1b, and Mdr2

110 Another SNP in CYP2B6 (983TT) and a p-glycoprotein haplotype affected AUCs without substanti

111 protein (humans, ABCG2; rodents, Abcg2) and P-glycoprotein (humans, ABCB1; rodents, Abcb1a/b) affect

112 mortem human brain tissue support a role for P-glycoprotein in clearance of cerebral beta-amyloid acr

113 ar, our findings show that the expression of P-glycoprotein in humans is compatible with the inherent

114 ction was not dependent on the expression of P-glycoprotein in MDR cells.

115 here is a highly localized overexpression of P-glycoprotein in the epileptogenic hippocampus of patie

116 nded-release venlafaxine (all substrates for P-glycoprotein) in a large randomized, prospective, prag

117 ionary related in full transporters, such as P-glycoprotein, in which substrates bind preferentially,

118 area, and concomitant use of cytochrome 3A4/P-glycoprotein inducers.

119 ostaglandin E2 receptors 1 and 2), abolished P-glycoprotein induction by C1P.

120 P-glycoprotein induction or activation to increase cereb

121 role for drug-drug interactions that lead to P-glycoprotein inhibition in buprenorphine-associated fa

122 We performed dose-response, synergism, P-glycoprotein inhibition, and pharmacokinetic studies i

123 associated with days of coadministration of P-glycoprotein inhibitor (r=0.35; p=0.0004).

124 Use of a P-glycoprotein inhibitor did not further increase the ef

125 G-829 as a novel, noncompetitive, and potent P-glycoprotein inhibitor that overcomes in vitro and in

126 olerability of NSC23925b, a novel and potent P-glycoprotein inhibitor, in rodents.

127 PSC833, a powerful P-glycoprotein inhibitor, significantly enhanced bupreno

128 Pretreatment with a P-glycoprotein inhibitor, which blocks blood-brain barri

129 trols then received a 30-min infusion of the P-glycoprotein-inhibitor tariquidar followed by another

130 presence of combined cytochrome P450 3A4 and P-glycoprotein inhibitors in the Rivaroxaban Once Daily

131 ere receiving concomitant treatment with the P-glycoprotein inhibitors quinidine or verapamil) or war

132 CL) cells with romidepsin in the presence of P-glycoprotein inhibitors to prevent transporter upregul

133 bodyweight [</=60 kg], or concomitant use of P-glycoprotein inhibitors) were present.

134 with >/= 1 combined cytochrome P450 3A4 and P-glycoprotein inhibitors.

135 hown a clear trend between lipophilicity and P-glycoprotein inhibitory activity for a class of galloy

136 less, or concomitant medication with potent P-glycoprotein interaction.

137 onedarone increases digoxin concentration by P-glycoprotein interaction.

138 psychotropic agents via cytochrome P450 and p-glycoprotein interactions.

139 It is a close homologue of human P-glycoprotein involved in multidrug resistance, and it

140 Our objectives were to assess P-glycoprotein involvement in norbuprenorphine transport

141 P-Glycoprotein is a well-known membrane transporter resp

142 nd does not affect other transporters; (iii) P-glycoprotein is expressed on the vascular endothelium

143 Wild-type and P-glycoprotein knockout female Friend virus B-type mice.

144 In P-glycoprotein-knockout mice, buprenorphine-related effe

145 However, lack of brain penetration and P-glycoprotein liability makes this scaffold unsuitable

146 ons to increase brain exposure by decreasing P-glycoprotein liability while maintaining potency and s

147 expression of the multidrug efflux transport P-glycoprotein may play an important role in pharmacores

148 ABCB1 (P-glycoprotein/MDR1) is a multidrug efflux transporter t

149 ced endosomal escape; (vi) the inhibition of P-glycoprotein mediated drug efflux; and (vii) the TAT-m

150 oducing fluorine on the risk of encountering P-glycoprotein mediated efflux (as measured by MDR efflu

151 nephine A (1) is a noncytotoxic inhibitor of P-glycoprotein-mediated drug efflux in multidrug-resista

152 sporters at the blood-brain barrier, such as P-glycoprotein, might contribute to pharmacoresistance b

153 in genes of mice, the Mdr1a, Mdr1b, and Mdr2 P-glycoproteins, now known as Abcb1a, Abcb1b, and Abcb4,

154 genes: CYP3A4, CYP3A5, ABCB1 (MDR1; encoding P-glycoprotein), NR1I2 (encoding the pregnane X receptor

155 lls in vivo by suppressing expression of the P-glycoprotein Oca2.

156 m infection replicated the in vivo impact of P-glycoprotein on anti-Cryptosporidium efficacy.

157 ofound effect of the drug-transporting ABCB1 P-glycoprotein on the pharmacokinetics of drugs in human

158 entrations of HG-829 restored sensitivity to P-glycoprotein oncolytic substrates.

159 binding cassette (ABC) transporter proteins, P-glycoprotein or breast cancer resistance protein.

160 ontributor to pharmacoresistance, overcoming P-glycoprotein overactivity could be investigated as a p

161 othesis that there is an association between P-glycoprotein overactivity in some regions of the brain

162 pectrometry to identify metabolic changes in P-glycoprotein overexpressing T-cell acute lymphoblastic

163 and 44 strongly inhibited the growth of the P-glycoprotein-overexpressing multi-drug-resistant cell

164 ARAP 22 showed strong inhibition of the P-glycoprotein-overexpressing NCI-ADR-RES and Messa/Dx5M

165 r initial acute injury for the prevention of P-glycoprotein overexpression, and thus this one potenti

166 he occurrence of seizures appears central to P-glycoprotein overexpression.

167 eased activity of efflux transporters, e.g., P-glycoprotein (P-gp) and breast cancer resistance prote

168 erexpression of the drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance prote

169 of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance prote

170 tive ligand of VDR, resulted in higher brain P-glycoprotein (P-gp) and lower soluble Abeta levels, ef

171 om treatment by efflux transporters, such as P-glycoprotein (P-gp) at the blood-brain barrier (BBB).

172 cess limited by drug efflux proteins such as P-glycoprotein (P-gp) at the membrane of brain capillary

173 The P-glycoprotein (P-gp) drug pump (ABCB1) has two transmem

174 S screening hit (1) that exhibited both high p-glycoprotein (P-gp) efflux ratios in rat and human and

175 As a substrate of the P-glycoprotein (P-gp) efflux transporter, quinacrine is

176 ssion and activity of the efflux transporter P-glycoprotein (P-gp) encoded by ABCB1 in human hepatoma

177 The drug efflux function of P-glycoprotein (P-gp) encoded by MDR1 can be influenced

178 ensitizers for photodynamic therapy (PDT) in P-glycoprotein (P-gp) expressing cells.

179 ecrease in ABCB1/multidrug resistance (MDR)1 p-glycoprotein (p-gp) expression.

180 Q-starch/siRNA complexes efficiently induced P-glycoprotein (P-gp) gene silencing in the human ovaria

181 Overexpression of ABC transporters like P-glycoprotein (P-gp) has been correlated with resistanc

182 The drug efflux pump P-glycoprotein (P-gp) has been shown to promote multidru

183 The mechanism reducing blood-brain barrier P-glycoprotein (P-gp) in Alzheimer's disease is poorly u

184 d cross-talk between the miR-221 network and P-glycoprotein (P-gp) in doxorubicin-induced drug resist

185 te to assess the activity of the transporter P-glycoprotein (P-gp) in humans.

186 and testes are limited due to high levels of P-glycoprotein (P-gp) in the luminal membranes of brain

187 lood-brain barrier is the efflux transporter P-glycoprotein (P-gp) in the luminal plasma membrane of

188 throughout the multidrug efflux transporter P-glycoprotein (P-gp) in three distinct conformational s

189 DR) is to deliver anticancer drug along with P-glycoprotein (P-gp) inhibitor simultaneously.

190 P-glycoprotein (P-gp) is a multidrug transporter that is

191 P-glycoprotein (P-gp) is a multidrug transporter that us

192 P-glycoprotein (P-gp) is a polyspecific ATP-dependent tr

193 P-glycoprotein (P-gp) is a well-known membrane transport

194 P-glycoprotein (P-gp) is an ATP binding cassette transpo

195 P-glycoprotein (P-gp) is an ATP-binding cassette drug pu

196 P-glycoprotein (P-gp) is an ATP-binding cassette transpo

197 The drug efflux transporter P-glycoprotein (P-gp) is highly expressed on brain endot

198 The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to be expressed at barrie

199 The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penet

200 ATP-binding cassette (ABC) drug transporter P-glycoprotein (P-gp) is often responsible for the failu

201 P-glycoprotein (P-gp) is one of the best-known mediators

202 P-glycoprotein (P-gp) largely influences the pharmacokin

203 The development of P-glycoprotein (P-gp) ligands remains of considerable in

204 P-glycoprotein (P-gp) plays a crucial role in the develo

205 drug resistance, the drug efflux behavior of P-glycoprotein (P-gp) remains a prominent challenge in c

206 P-glycoprotein (P-gp) serves as a therapeutic target for

207 study, we demonstrate that the inhibition of P-glycoprotein (P-gp) significantly increases brain pene

208 Here, we focus on the transporter P-glycoprotein (P-gp) that is partly responsible for lim

209 cking the multidrug resistance protein Mdr1a P-glycoprotein (P-gp) was generated using a rat Mdr1a-sp

210 P-glycoprotein (P-gp) was identified as the main efflux

211 ether this association might be mediated via P-glycoprotein (P-gp), a major pathway for clarithromyci

212 grows in tumours and functionally decreases P-glycoprotein (P-gp), a multidrug resistance transporte

213 P-glycoprotein (P-gp), a promiscuous drug efflux pump, h

214 increased the mRNA and protein expression of p-glycoprotein (P-gp), a subfamily of ATP-binding casset

215 P-glycoprotein (P-gp), also known as ABCB1, is a cell me

216 rimary determinant of CNS drug permeation is P-glycoprotein (P-gp), an endogenous blood-brain barrier

217 ractivity of multidrug transporters, such as P-glycoprotein (P-gp), at the blood-brain barrier.

218 on the transport activity and expression of P-glycoprotein (P-gp), breast cancer resistance protein

219 pumps, the ATP-Binding Cassette transporter P-glycoprotein (P-gp), consists of two homologous halves

220 Using P-glycoprotein (P-gp), Cyp3a-, and P-gp/Cyp3a knockout m

221 regulation of a multidrug resistant protein, P-glycoprotein (P-gp), suggesting an active drug efflux

222 e is connected to overexpression of membrane P-glycoprotein (P-gp), which acts as an energy dependent

223 epsy and subsequently to study if changes in P-glycoprotein (P-gp)-mediated efflux of flumazenil at t

224 ns such as the multidrug resistance protein, P-glycoprotein (P-gp).

225 ds 1-5 in biochemical assays with ABCC10 and P-glycoprotein (P-gp).

226 of the increased nuclear expression of MDR1/P-glycoprotein (P-gp).

227 uman multidrug resistance-linked transporter P-glycoprotein (P-gp).

228 rate of the multidrug resistance transporter P-glycoprotein (P-gp).

229 otosensitizer is also a potent stimulator of P-glycoprotein (P-gp).

230 transiently express c-Kit and stably express P-glycoprotein (P-gp)/multi-drug resistance type 1 (MDR1

231 activities against BCRP and screened against P-glycoprotein (P-gp, ABCB1) and multidrug resistance pr

232 clinically important because drug pumps like P-glycoprotein (P-gp, ABCB1) confer multidrug resistance

233 The P-glycoprotein (P-gp, ABCB1) drug pump protects us from

234 P-glycoprotein (P-gp, ABCB1) is an ATP-binding cassette

235 The multidrug transporter P-glycoprotein (P-gp, ABCB1) is an ATP-dependent pump th

236 P-glycoprotein (P-gp, ABCB1) is an important part of the

237 in the heart and increased the expression of P-glycoprotein (P-gp, ABCB1), an ATP binding cassette th

238 P-Glycoprotein (P-gp, ABCB1), multidrug resistance-assoc

239 LP), and presence of the efflux transporter, P-glycoprotein (P-gp, ABCB1).

240 vestigated compounds had low affinity toward P-glycoprotein (P-gp, ABCB1).

241 P-glycoprotein (P-gp, MDR1) is a promiscuous drug efflux

242 The ABC transporters P-glycoprotein (P-gp, official gene symbol ABCB1) and br

243 (11)C-metoclopramide transport by P-glycoprotein (P-gp; ABCB1) and the breast cancer resis

244 P-glycoprotein (P-gp; ABCB1) is an ABC drug pump that pr

245 wn substrate for efflux transporters such as P-glycoprotein (P-gp; MDR1, ABCB1), significantly less i

246 12, or 24 mg/kg/h) of cyclosporine A (CsA, a P-glycoprotein [P-gp] inhibitor).

247 rodrug and MDR gene-silencing siRNAs (Bcl-2, P-glycoprotein [P-gp], and survivin) via encapsulation a

248 e triphosphate-binding cassette transporters P-glycoprotein (Pgp) and breast cancer resistance protei

249 c resistance to olaparib caused by increased P-glycoprotein (Pgp) drug efflux transporter expression.

250 of vinca derivatives 16-18 able to modulate P-glycoprotein (Pgp) efflux activity is reported.

251 Overexpression of P-glycoprotein (Pgp) increases multidrug resistance (MDR

252 P-glycoprotein (Pgp) is an ATP-binding cassette (ABC) tr

253 P-glycoprotein (Pgp) is an efflux pump important in mult

254 P-glycoprotein (Pgp) is one of the most biomedically rel

255 The overexpression of P-glycoprotein (Pgp) is thought to be an important mecha

256 P-glycoprotein (Pgp) pumps an array of hydrophobic compo

257 Multidrug resistance (MDR) mediated by P-glycoprotein (Pgp) represents a significant impediment

258 uestration of the novel anti-tumor agent and P-glycoprotein (Pgp) substrate, di-2-pyridylketone-4,4-d

259 Saridegib, a known P-glycoprotein (Pgp) substrate, induced Pgp activity in

260 Localization of the drug transporter P-glycoprotein (Pgp) to the plasma membrane is thought t

261 resistance, are not only able to bypass the P-glycoprotein (Pgp) transporter, due to their nano-size

262 of administration and the inhibition of the P-glycoprotein (Pgp) transporter.

263 P-glycoprotein (Pgp), a member of the ATP-binding casset

264 P-glycoprotein (Pgp), a member of the ATP-binding casset

265 sed rather than decreased by the activity of P-glycoprotein (Pgp), a transporter conferring multidrug

266 of human cancers express multidrug-resistant P-glycoprotein (Pgp), which correlates with a poor progn

267 Both P-glycoprotein (Pgp)-dependent and non-Pgp-dependent mec

268 acyclines and other chemotherapeutics due to P-glycoprotein (pgp)-mediated export is a frequent probl

269 al cycle of the mouse ABC efflux transporter P-glycoprotein (Pgp; also known as ABCB1), which has a c

270 P-glycoproteins (Pgp) have been proposed as contributors

271 ily B member 1 (ABCB1) multidrug transporter P-glycoprotein plays a central role in clearance of xeno

272 The multispecific efflux transporter, P-glycoprotein, plays an important role in drug disposit

273 ilic drug doxorubicin hydrochloride and anti-P-glycoprotein siRNA, synergistic therapeutic activity i

274 nce predominantly involves overexpression of P-glycoprotein, so AZD2461 was developed as a poor subst

275 inhibitor of the ABC-B/multidrug resistance/P-glycoprotein subfamily of transporters in land plants,

276 articipants had a baseline PET scan with the P-glycoprotein substrate (R)-[(11)C]verapamil.

277 ve, sodium channel blocker and a fluorescent p-glycoprotein substrate that was traceable.

278 d decreased by 50% brain accumulation of the P-glycoprotein substrate verapamil.

279 ed controls (n = 9) using PET with a labeled P-glycoprotein substrate, (11)C-verapamil, and (15)O-wat

280 interfere with the cellular defense protein P-glycoprotein, termed transporter interfering compounds

281 ications that markedly reduce recognition by P-glycoprotein, the key efflux transporter at the blood-

282 we have employed purified and reconstituted P-glycoprotein to study its interaction with ivacaftor a

283 SFN did not alter P-glycoprotein transport activity in brain and spinal co

284 C1P treatment induced P-glycoprotein transport activity in brain capillaries r

285 naling pathway that within minutes abolishes P-glycoprotein transport activity without altering trans

286 C1P induced P-glycoprotein transport activity without changing trans

287 g by sphingosine 1-phosphate decreases basal P-glycoprotein transport activity.

288 a signaling cascade to dynamically regulate P-glycoprotein transport at the BBB and offers potential

289 The quiescent, nucleotide-free state in the P-glycoprotein transport cycle appears to bind ivacaftor

290 ed PCFT-nullizygous mice exhibited increased P-glycoprotein transport following VPA exposure.

291 c acid (VPA; 5 muM), significantly increased P-glycoprotein transport function in the wild-type anima

292 rather acts as a noncompetitive modulator of P-glycoprotein transport function.

293 However, VPA- or TCDD-induced P-glycoprotein transport was blocked in the PCFT-nullizy

294 luxed out of normal proximal tubules through P-glycoprotein transporter while being retained in cance

295 f sterol and sphingolipid regulation of ABCB/P-glycoprotein transporters.

296 ssette subfamily (ABC-B/multidrug resistance/P-glycoprotein) transporters from land plants have homol

297 that is overexpressed in MDR cancer cells is P-glycoprotein, which actively effluxes drugs against a

298 The ABCB1 gene encodes P-glycoprotein, which limits brain concentrations of cer

299 ytochrome P450 3A, and the drug transporter, P-glycoprotein, which predisposes these agents to many d

300 oxin (TCDD), produced a similar induction of P-glycoprotein, which tightened the BBB, thereby increas